Spots Global Cancer Trial Database for gej cancer
Every month we try and update this database with for gej cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT01697072 | Gastric Cancer | Rilotumumab Placebo Epirubicin Cisplatin Capecitabine | 18 Years - 99 Years | Amgen | |
| A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer | NCT05567835 | Gastric Adenoca... Gastroesophagea... | Fluorouracil Leucovorin Oxaliplatin Docetaxel GSCF | 18 Years - | Baylor College of Medicine | |
| Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer | NCT00858338 | Gastric Cancer Stomach Cancer | Potentially cur... Floxuridine (IP... Adjuvant Chemor... | 18 Years - | NYU Langone Health | |
| First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT01697072 | Gastric Cancer | Rilotumumab Placebo Epirubicin Cisplatin Capecitabine | 18 Years - 99 Years | Amgen | |
| Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors | NCT05945823 | Locally Advance... Esophageal Aden... Esophageal Squa... Siewert Type 1 ... Pancreatic Canc... | Futibatinib Pembrolizumab Cisplatin 5-FU Oxaliplatin Leucovorin Levoleucovorin Irinotecan | 18 Years - | Taiho Oncology, Inc. | |
| First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma | NCT01697072 | Gastric Cancer | Rilotumumab Placebo Epirubicin Cisplatin Capecitabine | 18 Years - 99 Years | Amgen | |
| Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer | NCT04847466 | Gastroesophagea... Advanced HNSCC | N-803 Pembrolizumab PD-L1 t-haNK | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer | NCT00858338 | Gastric Cancer Stomach Cancer | Potentially cur... Floxuridine (IP... Adjuvant Chemor... | 18 Years - | NYU Langone Health | |
| Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer | NCT00858338 | Gastric Cancer Stomach Cancer | Potentially cur... Floxuridine (IP... Adjuvant Chemor... | 18 Years - | NYU Langone Health | |
| A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer | NCT02137343 | Gastric Cancer | Rilotumumab Placebo Cisplatin Capecitabine | 20 Years - 100 Years | Amgen | |
| A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2) | NCT03861793 | Advanced Solid ... | ALKS 4230 Pembrolizumab | 18 Years - | Mural Oncology, Inc | |
| A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer | NCT02137343 | Gastric Cancer | Rilotumumab Placebo Cisplatin Capecitabine | 20 Years - 100 Years | Amgen | |
| Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | NCT02578368 | Gastric Cancer | 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel Trastuzumab sodium folinate Surgery | 18 Years - | Krankenhaus Nordwest | |
| A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer | NCT05567835 | Gastric Adenoca... Gastroesophagea... | Fluorouracil Leucovorin Oxaliplatin Docetaxel GSCF | 18 Years - | Baylor College of Medicine |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
